stockportfolio.pro
Oruka Therapeutics, Inc. (ORKA)
Healthcare · Biotechnology · NasdaqGM
Oruka Therapeutics, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-11.45M | $-16.44M | $-18.49M | $-7.93M | $-5.48M | $-9.74M | $-19.32M | $-9.93M | $-5.34M | $-105.43M |
| Net margin | — | — | — | — | — | — | — | — | — | — |
Source: Oruka Therapeutics, Inc. SEC filings (10-K). 21 years of history available in the interactive view.
Explore 21 years of Oruka Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ORKA in your portfolio →
Oruka Therapeutics, Inc. financial history by metric
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Oruka Therapeutics, Inc. — frequently asked questions
What is Oruka Therapeutics, Inc.'s revenue?
Oruka Therapeutics, Inc. (ORKA) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Oruka Therapeutics, Inc. profitable?
No — ORKA reported a net loss of $-105.43M in fiscal 2025.
What is ORKA's P/E ratio?
Oruka Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Oruka Therapeutics, Inc. have?
As of fiscal year 2025, ORKA carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Oruka Therapeutics, Inc.'s market cap?
Oruka Therapeutics, Inc. (ORKA) has a market capitalization of about $4.19B, based on the latest data in our nightly-refreshed cache.
When does Oruka Therapeutics, Inc.'s fiscal year end?
ORKA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Oruka Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 21 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.